AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19699071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18201459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal passive humidifiers (NPHs) applied in both nostrils for 1 hour on the 2nd postoperative day
Number of subjects: 40
Study 15738285 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiopsy
Number of subjects: 21
Study 15738285 — intervention group
Group type: COMPARATOR
Intervention: Bergström biopsy
Number of subjects: 21
Study 12088774 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV (SDNN <65.3 ms)
Number of subjects: 127
Study 12088774 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in SDNN
Number of subjects: 127
Study 10201103 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompting to manipulate leisure items
Number of subjects: 2
Study 10201103 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing object manipulation
Number of subjects: 2
Study 10201103 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking SIB while reinforcing manipulation
Number of subjects: 2
Study 10201103 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventing SIB with protective equipment while reinforcing object manipulation
Number of subjects: 2
Study 7794069 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day recombinant human growth hormone (rhGH)
Number of subjects: 10
Study 7794069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2218422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg b.i.d.
Number of subjects: 84
Study 2218422 — intervention group
Group type: COMPARATOR
Intervention: Pivmecillinam 700 mg t.i.d.
Number of subjects: 84
Study 334225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0
Study 334225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28810477 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy self-help intervention (self-help booklet and telephone support)
Number of subjects: 0
Study 28810477 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 31046819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐fortified lentils
Number of subjects: 1260
Study 31046819 — intervention group
Group type: COMPARATOR
Intervention: Unfortified lentils
Number of subjects: 1260
Study 31046819 — intervention group
Group type: COMPARATOR
Intervention: Usual intake
Number of subjects: 1260
Study 29103664 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 215
Study 29103664 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 215
Study 29103664 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 215
Study 29103664 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 215
Study 29103664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 25168676 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P-Positive Parenting Program
Number of subjects: 76
Study 25168676 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 76
Study 23783081 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinvaxem(®) vaccine administered at 6, 10, and 14 weeks of age
Number of subjects: 0
Study 23783081 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinvaxem(®) vaccine
Number of subjects: 0
Study 21272273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 129
Study 21272273 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training for symptom management
Number of subjects: 129
Study 21272273 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 129
Study 21272273 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 1 (highest openness score)
Number of subjects: 129
Study 21272273 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 3 (highest extraversion score)
Number of subjects: 129
Study 21272273 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 129
Study 19057416 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal formula (equivalent to 3,150 mg dry herb)
Number of subjects: 93
Study 19057416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 16378147 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative duplex scan before varicose vein surgery
Number of subjects: 293
Study 16378147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative duplex scan)
Number of subjects: 293
Study 16378147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of VV patients
Number of subjects: 293
Study 14615473 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% oral solution of levetiracetam (750 mg)
Number of subjects: 24
Study 14615473 — intervention group
Group type: COMPARATOR
Intervention: 750-mg tablet of levetiracetam
Number of subjects: 24
Study 12789964 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline microspheres plus scaling and root planing (SRP)
Number of subjects: 921
Study 12789964 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline microspheres plus SRP
Number of subjects: 921
Study 12789964 — intervention group
Group type: COMPARATOR
Intervention: SRP plus vehicle (placebo)
Number of subjects: 921
Study 12789964 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 921
Study 12789964 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline microspheres
Number of subjects: 921
Study 9589819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1%-salicylic acid 5% ointment
Number of subjects: 408
Study 9589819 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate 0.1% ointment
Number of subjects: 408
Study 8025983 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg daily)
Number of subjects: 58
Study 8025983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 2638464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oradyne‐Z mouthwash
Number of subjects: 24
Study 2638464 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 24
Study 2638464 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 24
Study 969820 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 2
Study 969820 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol, Propranolol, Verapamil, Calcium chloride
Number of subjects: 2
Study 30773266 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (aiming at 3 mg daily for 12 weeks)
Number of subjects: 33
Study 30773266 — intervention group
Group type: COMPARATOR
Intervention: Control period (5 weeks)
Number of subjects: 33
Study 28103158 — intervention group
Group type: EXPERIMENTAL
Intervention: sumatriptan iontophoretic transdermal system (TDS)
Number of subjects: 0
Study 28103158 — intervention group
Group type: EXPERIMENTAL
Intervention: lasmiditan
Number of subjects: 0
Study 28103158 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU‐142633
Number of subjects: 0
Study 28103158 — intervention group
Group type: EXPERIMENTAL
Intervention: NOX‐188
Number of subjects: 0
Study 28103158 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT1F receptor agonist lasmiditan
Number of subjects: 0
Study 28103158 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT2B and 5‐HT7 receptor antagonism
Number of subjects: 0
Study 25371534 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine (50 µg varicella-zoster virus glycoprotein E [gE] combined with AS01B adjuvant)
Number of subjects: 123
Study 25371534 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 123
Study 25371534 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 123
Study 23547788 — intervention group
Group type: EXPERIMENTAL
Intervention: E. guineensis leaf extract 500 mg
Number of subjects: 30
Study 23547788 — intervention group
Group type: EXPERIMENTAL
Intervention: E. guineensis leaf extract 1000 mg
Number of subjects: 30
Study 23547788 — intervention group
Group type: EXPERIMENTAL
Intervention: F. deltoidea leaf extract 1000 mg
Number of subjects: 30
Study 23547788 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 30
Study 20714991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lutein supplementation
Number of subjects: 0
Study 20714991 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed lutein/omega-3-fatty acid combination
Number of subjects: 0
Study 20714991 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-wavelength reflection method
Number of subjects: 0
Study 20714991 — intervention group
Group type: COMPARATOR
Intervention: 2-wavelength auto-fluorescence method
Number of subjects: 0
Study 20073226 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) on the bilateral Zusanli (ST36) and Tianshu (ST25) points
Number of subjects: 66
Study 20073226 — intervention group
Group type: COMPARATOR
Intervention: Citrate-mosapride tablet
Number of subjects: 66
Study 16427930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileocolonoscopy by trainees
Number of subjects: 100
Study 16427930 — intervention group
Group type: COMPARATOR
Intervention: Ileocolonoscopy by seniors
Number of subjects: 100
Study 16427930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileoscopy skill measurements
Number of subjects: 100
Study 14723858 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation of the primary respiratory mechanism (PRM)
Number of subjects: 49
Study 11691566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (25 mg/kg/bid) for 5 days
Number of subjects: 138
Study 11691566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (25 mg/kg/bid) for 10 days
Number of subjects: 138
Study 9143642 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 20 mg once a day
Number of subjects: 12
Study 9143642 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 5 mg three times a day
Number of subjects: 12
Study 9143642 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 10 mg three times a day
Number of subjects: 12
Study 9143642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31187203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB)
Number of subjects: 80
Study 31187203 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonist monotherapy
Number of subjects: 80
Study 29926560 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced nurse triage during overcrowding periods
Number of subjects: 0
Study 29926560 — intervention group
Group type: COMPARATOR
Intervention: Conventional triage
Number of subjects: 0
Study 26592857 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 66
Study 26592857 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 24684171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-train stimulation within the pedicle track using a ball-tipped probe and electromyography from lower limb muscles
Number of subjects: 71
Study 23460709 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m(2) on days 1, 22, and 43 combined with 70 Gy of radiotherapy (arm A)
Number of subjects: 204
Study 23460709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m(2) on days 1, 22, and 43 combined with 70 Gy of radiotherapy and erlotinib 150 mg per day (arm B)
Number of subjects: 204
Study 23460709 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and radiotherapy (arm A)
Number of subjects: 204
Study 23460709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and radiotherapy with erlotinib (arm B)
Number of subjects: 204
Study 19698856 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative statin therapy
Number of subjects: 17643
Study 17979577 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe ADHD treatment
Number of subjects: 303
Study 17979577 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-morbid communication disorders
Number of subjects: 303
Study 17979577 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 303
Study 15494637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy concurrently with weekly gemcitabine at 300 mg/m2
Number of subjects: 9
Study 11710635 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 i.v. bolus) followed 24 h later by paclitaxel (200 mg/m2 i.v. over 3 h)
Number of subjects: 28
Study 11710635 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 i.v. bolus) followed 30 min later by paclitaxel (200 mg/m2 i.v. over 3 h)
Number of subjects: 28
Study 9741730 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP group
Number of subjects: 29
Study 9741730 — intervention group
Group type: COMPARATOR
Intervention: Oxygen group
Number of subjects: 29
Study 9741730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation group
Number of subjects: 29
Study 8045206 — intervention group
Group type: EXPERIMENTAL
Intervention: First group intestinal preparation
Number of subjects: 6
Study 8045206 — intervention group
Group type: COMPARATOR
Intervention: Second group intestinal preparation
Number of subjects: 6
Study 8045206 — intervention group
Group type: COMPARATOR
Intervention: Third group intestinal preparation
Number of subjects: 6
Study 3198299 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin propionate-N-acetylcysteinate (EPAC)
Number of subjects: 12
Study 3198299 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate (ES)
Number of subjects: 12
Study 3198299 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC)
Number of subjects: 12
Study 1119589 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hospitalization
Number of subjects: 141
Study 1119589 — intervention group
Group type: COMPARATOR
Intervention: Long-term hospitalization
Number of subjects: 141
Study 31436475 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 - two bleaching sessions with violet LED light (405-410 nm), 30 min each session
Number of subjects: 50
Study 31436475 — intervention group
Group type: COMPARATOR
Intervention: G1 - two bleaching sessions with 35% carbamide peroxide, 30 min each session
Number of subjects: 50
Study 31436475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 30682044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 8
Study 30682044 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 8
Study 30682044 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 27317414 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (1, 2.5 and 5 g or 2 × 2.5 g 1 h apart)
Number of subjects: 46
Study 27317414 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (doses ≥2.5 g)
Number of subjects: 46
Study 27317414 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 46
Study 27317414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26637922 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 115
Study 26637922 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel
Number of subjects: 115
Study 24431895 — intervention group
Group type: EXPERIMENTAL
Intervention: LdT (600 mg/d orally) + ADV (10 mg/d orally)
Number of subjects: 106
Study 24431895 — intervention group
Group type: COMPARATOR
Intervention: LAM (100 mg/d orally) + ADV (10 mg/d orally)
Number of subjects: 106
Study 24431895 — intervention group
Group type: EXPERIMENTAL
Intervention: LdT + ADV
Number of subjects: 106
Study 24431895 — intervention group
Group type: COMPARATOR
Intervention: LAM + ADV
Number of subjects: 106
Study 21370724 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 6 weeks
Number of subjects: 24
Study 21370724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21370724 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 24
Study 18450930 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for late-life depression (structured conditions for up to 12 weeks)
Number of subjects: 461
Study 17905084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL
Number of subjects: 126
Study 17905084 — intervention group
Group type: COMPARATOR
Intervention: Regular PCNL
Number of subjects: 126
Study 14679117 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 (arm A)
Number of subjects: 182
Study 14679117 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 (arm B)
Number of subjects: 182
Study 11136915 — intervention group
Group type: COMPARATOR
Intervention: Acute phase of stroke
Number of subjects: 106
Study 11136915 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent period
Number of subjects: 106
Study 9134632 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for up to six months (discontinued after the first event)
Number of subjects: 380
Study 9134632 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with factor V Leiden
Number of subjects: 380
Study 9134632 — intervention group
Group type: COMPARATOR
Intervention: Patients without factor V Leiden
Number of subjects: 380
Study 7696826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sangemini mineral water
Number of subjects: 18
Study 7696826 — intervention group
Group type: COMPARATOR
Intervention: Milk calcium
Number of subjects: 18
Study 3585679 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine chewing gum
Number of subjects: 20
Study 3585679 — intervention group
Group type: COMPARATOR
Intervention: Chewing gum without nicotine (placebo)
Number of subjects: 20
Study 31268011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy
Number of subjects: 84
Study 31268011 — intervention group
Group type: COMPARATOR
Intervention: Infusion therapy
Number of subjects: 84
Study 27986370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 275
Study 27986370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ethyl chloride spray)
Number of subjects: 275
Study 24739800 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 119
Study 24739800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 23881346 — intervention group
Group type: EXPERIMENTAL
Intervention: BIB® (6 months) followed by diet therapy (7 months)
Number of subjects: 50
Study 23881346 — intervention group
Group type: COMPARATOR
Intervention: Consecutive BIB® placement for 6 months followed by another BIB® for 6 months (with a 1-month interval)
Number of subjects: 50
Study 21976264 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-oriented Occupational Therapy methods
Number of subjects: 150
Study 21976264 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 19908309 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS ON
Number of subjects: 14
Study 19908309 — intervention group
Group type: COMPARATOR
Intervention: DBS OFF
Number of subjects: 14
Study 16924183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation exercise program
Number of subjects: 54
Study 16924183 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 54
Study 16924183 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 15481405 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site shielding
Number of subjects: 0
Study 15481405 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous broadband RF recording
Number of subjects: 0
Study 15481405 — intervention group
Group type: COMPARATOR
Intervention: Simple sleep monitoring systems based on single-channel EEG analysis
Number of subjects: 0
Study 11533340 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein, energy, mineral, and micronutrient-enriched postdischarge formula (PDF; N = 113)
Number of subjects: 284
Study 11533340 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula (TF; N = 116)
Number of subjects: 284
Study 11533340 — intervention group
Group type: COMPARATOR
Intervention: Breastfed until at least 6 weeks' postterm (Reference group; N = 65)
Number of subjects: 284
Study 11533340 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein, energy, mineral, and micronutrient-enriched postdischarge formula (PDF)
Number of subjects: 284
Study 11533340 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula (TF)
Number of subjects: 284
Study 9751013 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix B (1 ml, 20 micrograms)
Number of subjects: 76
Study 9751013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepavax (1 ml, 20 micrograms)
Number of subjects: 76
Study 9751013 — intervention group
Group type: EXPERIMENTAL
Intervention: Gen Hevac B (combined S and PreS subunit vaccine, 1 ml, 20 micrograms)
Number of subjects: 76
Study 9751013 — intervention group
Group type: COMPARATOR
Intervention: Standard isolated S-antigen-containing vaccines (Engerix B or Hepavax)
Number of subjects: 76
Study 7841897 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 20
Study 7841897 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 20
Study 3411179 — intervention group
Group type: COMPARATOR
Intervention: Human chorionic gonadotropin (hCG) 1500 IU intramuscularly on days +4, +7, +10, and +13
Number of subjects: 17
Study 3411179 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone in oil 25 mg intramuscularly daily from day +4 to day +18
Number of subjects: 17
Study 31654535 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-free regimens
Number of subjects: 0
Study 31654535 — intervention group
Group type: COMPARATOR
Intervention: Interferon-based regimens
Number of subjects: 0
Study 29040974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 127
Study 29040974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 127